Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953374 | 0.85 | F2RL1 (0.49) | KMT2AGLASMN1; SMN2ALDH1A1RECQL | |
| SCHEMBL10420886 | 0.83 | HTT (0.43) | KMT2AALDH1A1RECQLTHRBPKM | |
| SCHEMBL13953253 | 0.81 | ALOX5 (0.45) | KMT2AGLASMN1; SMN2ALOX5ALDH1A1 | |
| SCHEMBL10296083 | 0.80 | ALDH1A1 (0.55) | KMT2ASMN1; SMN2ALDH1A1RECQLTHRB | |
| SCHEMBL13953042 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALOX5ALDH1A1F2RL1 | |
| SCHEMBL5891307 | 0.75 | PKM (0.50) | KMT2AALDH1A1RECQLTHRBPKM | |
| SCHEMBL13953045 | 0.72 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2ALOX5F2RL1 | |
| SCHEMBL13953043 | 0.72 | GLA (0.48) | KMT2AGLAALOX5ALDH1A1F2RL1 | |
| SCHEMBL13953254 | 0.71 | SMN1; SMN2 (0.43) | KMT2AGLASMN1; SMN2ALOX5ALDH1A1 | |
| SCHEMBL11401927 | 0.71 | PKM (0.43) | KMT2AALDH1A1RECQLTHRBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7189748-B2 | Compounds and methods for treating insulin resistance and cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | CPT1A, CPT1B, PNLIP | KMT2A 4086/4885GLA 2004/4885SMN1; SMN2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.